Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres-Reference-Cited by-同舟云学术

Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres

Published:2020-04 Issue:2 Volume:11 Page:366-375
ISSN:2078-6891
Container-title:Journal of Gastrointestinal Oncology
language:
Short-container-title:J Gastrointest Oncol

Author:

Vogl Ursula M.,Vormittag Laurenz,Winkler Thomas,Kafka Alice,Weiser-Jasch Olivia,Heinrich Bettina,Roider-Schur Sophie,Andalibi Haleh,Autzinger Eva,Schima Wolfgang,Klaus Alexander,Zacherl Johannes,Wimberger Günter Michael,Öhler Leopold

Publisher

AME Publishing Company

Subject

Gastroenterology,Oncology

Link

http://jgo.amegroups.com/article/download/37787/pdf

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option;Frontiers in Oncology;2024-08-13

2. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415);BMC Cancer;2023-06-19

3. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO;European Journal of Cancer;2022-04

4. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort;BMC Cancer;2022-01-10

5. Nivolumab as a representative of immune checkpoint inhibitors in late-line treatment for disseminated gastric cancer;Meditsinskiy sovet = Medical Council;2021-08-07